• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

益生菌临床试验的全球分析。

Global analysis of clinical trials with probiotics.

作者信息

Dronkers Theresia M G, Ouwehand Arthur C, Rijkers Ger T

机构信息

Department of Sciences, University College Roosevelt, Lange Noordstraat 1, 4331 CB, Middelburg, the Netherlands.

DuPont Nutrition and Biosciences, Danisco Sweeteners Oy, Sokeritehtaantie, Kantvik, 02460, Finland.

出版信息

Heliyon. 2020 Jul 17;6(7):e04467. doi: 10.1016/j.heliyon.2020.e04467. eCollection 2020 Jul.

DOI:10.1016/j.heliyon.2020.e04467
PMID:32715136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7371762/
Abstract

Over 1,000 clinical studies with probiotics, registered at ClinicalTrials.gov and/or the International Clinical Trials Registry Platform (ICTRP) of the World Health Organization, have addressed over 700 different diseases and conditions. The average size of a clinical trial with probiotics (74 participants) is comparable to the overall average of all studies in ClincialTrials.gov. GG (LGG) and ssp. BB12 are the probiotic strains studied most. The exact composition of the product which is used, including the dosage, is not always indicated in the registry. The majority of probiotics studies at ClinicalTrials.gov is registered in the USA or Europe (56%). The data from ICTRP show the rapid expansion of clinical studies with probiotics in Asia, notably Iran and China.

摘要

在ClinicalTrials.gov和/或世界卫生组织国际临床试验注册平台(ICTRP)上注册的、超过1000项有关益生菌的临床研究,涉及700多种不同疾病和状况。益生菌临床试验的平均规模(74名参与者)与ClinicalTrials.gov上所有研究的总体平均规模相当。鼠李糖乳杆菌GG(LGG)和嗜热栖热放线菌BB12是研究最多的益生菌菌株。注册信息中并不总是标明所使用产品的确切成分,包括剂量。ClinicalTrials.gov上的大多数益生菌研究是在美国或欧洲注册的(56%)。ICTRP的数据显示,亚洲尤其是伊朗和中国有关益生菌的临床研究正在迅速扩展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4db4/7371762/0286c9f794da/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4db4/7371762/a1e208d24f2b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4db4/7371762/0286c9f794da/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4db4/7371762/a1e208d24f2b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4db4/7371762/0286c9f794da/gr2.jpg

相似文献

1
Global analysis of clinical trials with probiotics.益生菌临床试验的全球分析。
Heliyon. 2020 Jul 17;6(7):e04467. doi: 10.1016/j.heliyon.2020.e04467. eCollection 2020 Jul.
2
Impact of probiotics on development and behaviour in Drosophila melanogaster - a potential in vivo model to assess probiotics.益生菌对黑腹果蝇发育和行为的影响 - 一种评估益生菌的潜在体内模型。
Benef Microbes. 2019 Mar 13;10(2):179-188. doi: 10.3920/BM2018.0012. Epub 2018 Dec 21.
3
Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens.益生菌乳酸杆菌和双歧杆菌对肠道及尿道病原体的拮抗活性。
J Appl Microbiol. 2006 Jun;100(6):1324-32. doi: 10.1111/j.1365-2672.2006.02857.x.
4
Probiotics for prevention and treatment of diarrhea.益生菌预防和治疗腹泻。
J Clin Gastroenterol. 2011 Nov;45 Suppl:S149-53. doi: 10.1097/MCG.0b013e3182257e98.
5
Turmeric Extract: Potential Use as a Prebiotic and Anti-Inflammatory Compound?姜黄提取物:作为一种益生元和抗炎化合物的潜在用途?
Plant Foods Hum Nutr. 2019 Sep;74(3):293-299. doi: 10.1007/s11130-019-00733-x.
6
Characterization of potentially probiotic lactic acid bacteria and bifidobacteria isolated from human colostrum.从人初乳中分离的潜在益生菌乳酸菌和双歧杆菌的特性。
J Dairy Sci. 2020 May;103(5):4013-4025. doi: 10.3168/jds.2019-17602. Epub 2020 Feb 26.
7
Effect of kynurenic acid on the viability of probiotics in vitro.犬尿酸对益生菌体外生存力的影响。
Pharmacol Rep. 2011;63(2):548-51. doi: 10.1016/s1734-1140(11)70522-9.
8
Effect of Bauer and ssp. BB12 on proteolytic changes in dry-cured loins.鲍尔氏菌及亚种BB12对干腌猪腰肉蛋白水解变化的影响。
Food Sci Biotechnol. 2017 Jun 8;26(3):633-641. doi: 10.1007/s10068-017-0076-4. eCollection 2017.
9
Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats.富含低聚果糖的益生元菊粉与益生菌鼠李糖乳杆菌和乳酸双歧杆菌联合使用对大鼠偶氮甲烷诱导的结肠癌发生的抗肿瘤活性。
Carcinogenesis. 2002 Nov;23(11):1953-60. doi: 10.1093/carcin/23.11.1953.
10
Intestinal colonisation, microbiota and future probiotics?肠道定植、微生物群与未来的益生菌?
Asia Pac J Clin Nutr. 2006;15(4):558-62.

引用本文的文献

1
Lactobacilli biology, applications and host interactions.乳酸杆菌的生物学特性、应用及与宿主的相互作用。
Nat Rev Microbiol. 2025 Jul 23. doi: 10.1038/s41579-025-01205-7.
2
Applications of bacteriophages in precision engineering of the human gut microbiome.噬菌体在人类肠道微生物组精准工程中的应用。
Eng Microbiol. 2025 Jan 6;5(1):100189. doi: 10.1016/j.engmic.2025.100189. eCollection 2025 Mar.
3
The ladder of regulatory stringency and balance: an application to the US FDA's regulation of bacterial live therapeutics.监管严格性与平衡性的阶梯:应用于美国食品药品监督管理局对细菌活菌疗法的监管

本文引用的文献

1
Death and the Miser: microbiota regulate the outcome of checkpoint inhibition immunotherapy.《死神与守财奴:微生物群调节免疫检查点抑制疗法的疗效》
Expert Rev Anticancer Ther. 2019 Oct;19(10):831-834. doi: 10.1080/14737140.2019.1677158. Epub 2019 Oct 12.
2
Development of omics-based protocols for the microbiological characterization of multi-strain formulations marketed as probiotics: the case of VSL#3.基于组学的多菌株配方(如 VSL#3)微生物特征分析方案的开发。
Microb Biotechnol. 2019 Nov;12(6):1371-1386. doi: 10.1111/1751-7915.13476. Epub 2019 Aug 12.
3
Probiotics Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells.
Gut Microbes. 2025 Dec;17(1):2517377. doi: 10.1080/19490976.2025.2517377. Epub 2025 Jun 12.
4
Gut microbiota and their influence in brain cancer milieu.肠道微生物群及其在脑癌微环境中的影响。
J Neuroinflammation. 2025 May 1;22(1):129. doi: 10.1186/s12974-025-03434-2.
5
Allergenicity, Genotoxicity and Subchronic Toxicity Assessment of IgG Binding Protein LT Produced From Aspergillus oryzae.米曲霉产生的IgG结合蛋白LT的致敏性、遗传毒性和亚慢性毒性评估
J Appl Toxicol. 2025 Aug;45(8):1614-1636. doi: 10.1002/jat.4787. Epub 2025 Apr 27.
6
Genetic and phenotypic stability of DG (DSM 34154) over 10 years of industrial production.DG(DSM 34154)在10年工业生产过程中的遗传和表型稳定性。
Appl Environ Microbiol. 2025 May 21;91(5):e0239424. doi: 10.1128/aem.02394-24. Epub 2025 Apr 24.
7
Should physicians prescribe probiotics alongside antibiotics? A practical perspective.医生应该在开抗生素的同时开益生菌吗?一个实际的观点。
Prz Gastroenterol. 2025;20(1):1-4. doi: 10.5114/pg.2025.148588. Epub 2025 Mar 17.
8
Nature's Arsenal: Uncovering Antibacterial Agents Against Antimicrobial Resistance.大自然的武器库:发现对抗抗菌药物耐药性的抗菌剂。
Antibiotics (Basel). 2025 Mar 1;14(3):253. doi: 10.3390/antibiotics14030253.
9
Bacteriocins from Lactic Acid Bacteria Could Modulate the Wnt Pathway: A Possible Therapeutic Candidate for the Management of Colorectal Cancer- An In silico Study.来自乳酸菌的细菌素可调节Wnt信号通路:一种用于结直肠癌治疗的潜在候选物——一项计算机模拟研究
Anticancer Agents Med Chem. 2025 Mar 12. doi: 10.2174/0118715206367950250228100833.
10
Metabolic engineering of Lactobacilli spp. for disease treatment.用于疾病治疗的乳酸杆菌属的代谢工程。
Microb Cell Fact. 2025 Mar 6;24(1):53. doi: 10.1186/s12934-025-02682-4.
益生菌通过抑制第三类固有淋巴细胞来消除免疫检查点阻断相关结肠炎。
Front Immunol. 2019 Jun 4;10:1235. doi: 10.3389/fimmu.2019.01235. eCollection 2019.
4
The pros, cons, and many unknowns of probiotics.益生菌的利与弊及诸多未知因素。
Nat Med. 2019 May;25(5):716-729. doi: 10.1038/s41591-019-0439-x. Epub 2019 May 6.
5
The ethics of reporting all the results of clinical trials.报告临床试验所有结果的伦理学问题。
Br Med Bull. 2017 Jan 1;121(1):19-29. doi: 10.1093/bmb/ldw058.
6
The Science behind the Probiotic Strain Bifidobacterium animalis subsp. lactis BB-12(®).益生菌菌株动物双歧杆菌乳亚种BB-12背后的科学。
Microorganisms. 2014 Mar 28;2(2):92-110. doi: 10.3390/microorganisms2020092.
7
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.慢性溃疡性结肠炎回肠储袋肛管吻合术后储袋炎的治疗与预防
Cochrane Database Syst Rev. 2015 Nov 23(11):CD001176. doi: 10.1002/14651858.CD001176.pub3.
8
Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic.专家共识文件。国际益生菌和益生元科学协会关于益生菌术语的范围和适当使用的共识声明。
Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14. doi: 10.1038/nrgastro.2014.66. Epub 2014 Jun 10.
9
The design of probiotic studies to substantiate health claims.益生菌研究设计以证实健康声称。
Gut Microbes. 2011 Sep 1;2(5):299-305. doi: 10.4161/gmic.2.5.18002.
10
Publication bias against negative results from clinical trials: three of the seven deadly sins.针对临床试验阴性结果的发表偏倚:七宗罪中的三宗。
Nat Clin Pract Neurol. 2007 Nov;3(11):590-1. doi: 10.1038/ncpneuro0618. Epub 2007 Sep 18.